Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
healthcare value value-based care money dollar

Startup focused on heart failure monitoring raises $25M with help from Novo Holdings, Medtronic

The round was led by two new investors, Novo Holdings and Andera Partners. Several existing investors, including Medtronic, also participated.

Thumbnail

Long-term fasting improves heart-related outcomes for at-risk COVID-19 patients

New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Thumbnail

High costs limit the value of dapagliflozin, empagliflozin as heart failure treatments

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

Atul Verma, MD, head of cardiology at McGill University Health Centre

Day 3 at ACC.23 features late-breaking studies on pulsed-field ablation, other new technologies

The third and final day of ACC.23 featured a key update on Medtronic's pulsed-field ablation technology and many other late-breaking clinical studies. 

ACC 2023 ACC.23 American College of Cardiology

Day 2 at ACC.23 features late-breaking studies on TEER, TAVR, EHR alerts and much more

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

Heart failure specialist Sean Pinney named new chief of cardiology at Mount Sinai Morningside

The move represents a return of sorts for Pinney, who served Mount Sinai in a variety of leadership roles from 2004 to 2020.

The Millipede 088 Access Catheter. Image courtesy of Perfuze. FDA clearance.

Regulatory Roundup: FDA clears 2 new solutions, declines to approve omecamtiv mecarbil for HFrEF

Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 

Displaying 169 - 176 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.